Amicus Therapeutics treats rare diseases with biotechnology. Their interest in genetic diseases has led to numerous treatments including migalastat. Migalastat is a candidate for the treatment of Fabry disease, and is based on the genetic diagnosis of the individual. Another development of Amicus Therapeutics is called SD-101, and it has reached the later stages in its development. This has been designed for the Epidermolysis Bullosa disorder which affects the connective tissues. Amicus Therapeutics strives to help the individuals suffering from rare diseases, and some of their candidates are expected to be the first available on the market.
The employees of Amicus Therapeutics joined forces and decided to create a statement that would reflect their beliefs, and values. This provided a reminder of why they work so hard every day, and what they hope to achieve. These beliefs are critical in understanding the strength of the commitment, and depth of passion Reflected by the proud employees of Amicus Therapeutics. They believe fighting to find therapies to help individuals with rare diseases is worth every moment of effort it requires. They strive to ensure their therapies provide the highest quality of help for these individuals (Indeed).
Amicus Therapeutics is about the community, individuals affected by serious diseases, and their families. The employees serve with passion, duty, new ideas, and technologies. Their core values represent their dedication to the work they do, their ability to accept new ideas, and the value of taking a smart risk. Amicus Therapeutics is not afraid to ask the really hard questions, and never limit themselves to outdated thinking. When they make a mistake, they gain knowledge, and experience, and continue their forward momentum.
Amicus Therapeutics reached for the future with a strong belief in science, strategic partnerships, and their shareholders. They price their medications fairly, make them accessible, and are responsible for their actions. They understand their success in the future is based on honesty, accountability, and teamwork. They make the contribution of every individual count, and communicate with diversity, respect, and a health balance. Although the employees of Amicus Therapeutics have fun, they never shirk their responsibilities.
More at http://weeklyopinion.com/2017/08/amicus-therapeutics-announces-the-launch-of-new-drug/
- Mark Holterman is a professor at the University of Illinois College Of Medicine, and he has worked there from 2011. Dr. Mark is also an attending pediatric surgeon at the Children’s Hospital of Illinois and Advocate Christ Children’s Hospital. Holterman has majored in pediatric surgery and is interested in research concerning obesity and novel cancer treatments as well as stem cell therapies and regenerative medicine.
Education and Career
Dr. Mark Holterman schooled at Yale University, where he majored in biology and graduated with honors before earning his MD and Ph.D. from the University of Virginia (LinkedIn). He later finalized a residency in general surgery at the University of Virginia Health Science and a fellowship at Children’s Medical Center through the University of Washington. Previously, Dr. Mark attended pediatric surgeon at Rush University Medical Center and also served at the Advocate Children’s Hospital as surgeon-in-chief.
Dr. Holterman’s Association with Sunshine Foundation
Given to his knowledge in regenerative therapies, Dr. Mark has helped in the founding of Cellular Therapies and the Sunshine Foundation. This idea was inspired by three individuals who had a successful cellular and regenerative therapy. One of the three persons received these regenerative therapies from Celltex Therapeutics, to treat dysautonomia and systemic juvenile idiopathic arthritis. Celltex uses stem cells, mesenchymal cell, during treatment. Mesenchymal stem cells are readily available in tissues across the human body but are plenty in fat tissues. The MSCs’ ability to flourish in various cells, such as muscle and bone, making them essential in improving healing, stopping cellular decay, combating inflammation, and formation of new blood vessels.
Dr. Mark Holterman Recognized
Dr. Mark Holterman has received several awards such as the Innovative Research Award by the American Diabetes Association. ADA is an organization focused on funding research, cures and preventive measures of diabetes. The group offers two different awards to professional; the Translational Science (ICTS) Award and the Basic Science (IBS) Award. The IBS is available to a faculty member at any level and given to a person who presents original and new hypothesis. ICTS awards are however granted to individuals whose researchers directly involve human data, subjects, and samples.
More about Dr. Mark Holterman https://www.osfhealthcare.org/physicians/profile/2358/mark-j-holterman-md-phd/